3-碘-5-硝基-1H-吲唑 | 70315-69-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 3-碘-5-硝基-1H-吲唑
• 英文名称: 3-iodo-5-nitro-1H-indazole
• 英文别名: 3-iodo-5-nitro-2H-indazole
• CAS: 70315-69-4
• 化学式: C₇H₄IN₃O₂
• 分子量: 289.032
• InChiKey: UCTRCMYXPOXOSN-UHFFFAOYSA-N

物化性质

• 熔点：
  214 °C(Solv: ligroine (8032-32-4))
• 沸点：
  458.0±25.0 °C(Predicted)
• 密度：
  2.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Iodo-5-nitro-1H-indazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Iodo-5-nitro-1H-indazole
CAS number: 70315-69-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4IN3O2
Molecular weight: 289.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-碘-5-硝基-1H-吲唑 在 铁粉 、 sodium hydride 、 氯化铵 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙腈 为溶剂， 反应 3.83h， 生成 5-cyano-6-cyclopropyl-N-(3-cyclopropyl-1H-indazol-5-yl)-3,4-dimethylpicolinamide
  参考文献：
  名称：

  WO2021007477A5

  摘要：

  公开号：

  WO2021007477A5
• 作为产物：
  描述：

  5-硝基吲唑 在 碘 、 potassium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 96.0h， 以98%的产率得到3-碘-5-硝基-1H-吲唑
  参考文献：
  名称：

  鉴定3-磺酰基吲唑衍生物作为有效的和选择性的5-HT 6拮抗剂

  摘要：

  作为开发认知增强剂的努力的一部分，我们一直专注于5-HT 6受体，以便为此目的鉴定有效的和选择性的配体。在这里，我们报告鉴定具有有效的和选择性的5-HT 6拮抗剂的具有无环氨基侧链的一系列新的3-磺酰吲唑衍生物。报道了这类化合物的合成和详细的SAR。

  DOI：

  10.1016/j.bmc.2010.10.033

文献信息

• Synthesis of 3-Indazolecarboxylic Esters and Amides via Pd-Catalyzed Carbonylation of 3-Iodoindazoles
  作者：Hans-Peter Buchstaller、Kai Wilkinson、Kasimir Burek、Yasmin Nisar

  DOI：10.1055/s-0030-1260199

  日期：2011.10

  A straightforward and effective procedure for the preparation of 1H-indazole-3-carboxylic acid esters and amides was developed. A series of functionalized 3-iodoindazoles were subjected to Pd-catalyzed carbonylations in the presence of methanol or amines, yielding the title compounds in moderate to good yield. For the majority of examples, the reaction proceeded cleanly under mild conditions, which

  开发了一种简单有效的制备1 H-吲哚-3-羧酸酯和酰胺的方法。在甲醇或胺的存在下，对一系列官能化的3-碘吲唑进行Pd催化的羰基化反应，以中等至良好的收率得到标题化合物。对于大多数实例，反应在温和条件下干净地进行，该条件易于被允许进一步合成转化的多种官能团所耐受。 羰基化-酯-酰胺-烷氧基羰基化-氨基羰基化-碘吲唑-钯催化
• Discovery of 3-(Indol-5-yl)-indazole Derivatives as Novel Myeloid Differentiation Protein 2/Toll-like Receptor 4 Antagonists for Treatment of Acute Lung Injury
  作者：Zhiguo Liu、Lingfeng Chen、Pengtian Yu、Yali Zhang、Bo Fang、Chao Wu、Wu Luo、Xianxin Chen、Chenglong Li、Guang Liang

  DOI：10.1021/acs.jmedchem.9b00316

  日期：2019.6.13

  responses. Targeting the myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex may be a promising way to treat Gram-negative bacterial-induced inflammatory disorders. In this study, we report the design and synthesis of a new series of 3-(indol-5-yl)-indazoles, which were evaluated for their anti-inflammatory activities in macrophages. Among the analogues generated, the promising 3-(indol-5-yl)-indazole

  急性肺损伤（ALI）通常是由全身炎症反应引起的。靶向骨髓分化蛋白2 / toll样受体4（MD2-TLR4）复合物可能是治疗革兰氏阴性细菌引起的炎症性疾病的一种有前途的方法。在这项研究中，我们报告了一系列新的3-（吲哚-5-基）-吲唑的设计和合成，对它们在巨噬细胞中的抗炎活性进行了评估。在产生的类似物中，有希望的3-（吲哚-5-基）-吲唑类似物22m抑制脂多糖（LPS）诱导的巨噬细胞中肿瘤坏死因子α（TNF-α）和白细胞介素6（IL-6）的表达。 IC50值分别为0.89和0.53μM。然后在抑制LPS诱导的炎症反应中，将化合物22m鉴定为MD2-TLR4拮抗剂。体内给药22m可以显着抑制LPS攻击小鼠的肺组织巨噬细胞浸润并改善其组织病理学变化。我们的研究确定了一种新型的3-（吲哚-5-基）-吲唑22m作为有效的MD2-TLR4抑制剂，为将来开发用于治疗ALI的抗炎药奠定了基础。
• Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
  申请人：Elokdah Mahmoud Hassan

  公开号：US20070037802A1

  公开（公告）日：2007-02-15

  The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

  本发明提供了一种式I化合物及其用于治疗与5-HT6受体相关或受其影响的中枢神经系统疾病的用途。
• Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
  申请人：Elokdah Mahmoud Hassan

  公开号：US20070054896A1

  公开（公告）日：2007-03-08

  The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

  本发明提供了一种公式I的化合物，以及该化合物用于治疗与5-HT6受体相关或受其影响的神经中枢系统疾病的用途。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20140309225A1

  公开（公告）日：2014-10-16

  The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R 1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R 3 , R 4 , R 5 , n, and X 1 have the same definitions as those described in the specification), and R 2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和药物组合物。根据本发明，提供了由以下式（I）表示的烟酰胺衍生物或其盐， 其中 R 1 是由以下式（II-1）、（III-1）或（IV-1）表示的取代基 （其中R 3 、R 4 、R 5 、n和X 1 的定义与说明书中描述的相同），而R 2 是吡啶基、吲唑基、苯基、吡唑吡啶基、苯并异噁唑基、嘧啶基或喹啉基，每种基可选择地具有至少一个取代基。